The impact of continuous flow VAD on survival among patients awaiting heart transplant is not well known. Pts on the UNOS list were propensity score matched 1:2 (HeartMate II vs no VAD). Wait list mortality was 10% during the 7.5 year study. Use of a VAD improved survival to transplant at 1 (91% vs 77%) and 2 years (85% vs 68%). Use of VAD as a br
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant
September 4, 2014
Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial
August 16, 2014
In this multi-institution randomized trial, patients with heart failure underwent daily telemonitoring and standard care or just standard care. At 1 year, fewer patients in the telemonitoring group had worsened composite score (19% vs 27%) and experienced fewer deaths (10 vs 27 pts).
March 10, 2014
This video shows a female toddler with diagnosed idiopathic dilated cardiomyopathy. The patient presented with worsening symptoms of congestive heart failure and was treated with the help of a left ventricular assist device.